-
|
|
|
Other Names:
5 hydroxy-tryptophan, 5-hydroxytryptophan, 5-hydroxy L-tryptophan,
5-Hydroxy Tryptophan, 5-L-Hydroxytryptophan, L-5 HTP, L-5 hydroxytryptophan, Oxitriptan.
Classification:
Chemical By-Product / Nutritional Supplement
5-HTP (5-Hydroxytryptophan) is a chemical by-product of the protein building block
L-tryptophan. It is also produced commercially from the seeds of an African plant
(Griffonia simplicfolia).
5-HTP is used by the human body to make serotonin, an important substance for normal nerve
and brain function. Serotonin appears to play significant roles in sleep, emotional
moods, pain control, inflammation, intestinal peristalsis, and other body functions.
|
|
|
Saftey & Side Effects
During the clinical trials described above, some people taking large amounts of 5-HTP
experienced gastrointestinal upset (e.g. nausea) or, less often, headache, sleepiness,
muscle pain, or anxiety.
A substance known as "Peak X" has been found in low concentrations in several
over-the-counter 5-HTP preparations. Some researchers think this substance may be linked
to toxicity previously reported in a 1989 L-tryptophan contamination incident. However,
there is serious question about whether Peak X is actually the toxic agent and it may be
unrelated to the problems previously associated with L-tryptophan. Although two articles
reported possible associations between 5-HTP consumption and toxicity symptoms similar to
those attributed to contaminated L-tryprophan, evidence linking 5-HTP or Peak X with any
toxicity symptoms remains speculative. Although the structure of Peak X has recently been
identified, there is no firm evidence that this substance has caused or contributed to any
toxicity or disease.
Very high intakes of 5-HTP have caused muscle jerks in guinea pigs and both muscle jerks
and diarrhea in mice. Injected 5-HTP has also caused kidney damage in rats. To date, these
problems have not been reported in humans. "Serotonin syndrome," a serious but uncommon
condition caused by excessive amounts of serotonin, has not been reported to result from
supplementation with 5-HTP; in theory it could be triggered by the supplement. However,
the level of intake at which this toxic effect might potentially occur remains unknown.
5-HTP should not be taken with antidepressants, weight-control drugs, other
serotonin-modifying agents, or substances known to cause liver damage, because in these
cases 5-HTP may have excessive effects. People with liver disease may not be able to
regulate 5-HTP adequately and those suffering from autoimmune diseases such as scleroderma
may be more sensitive than others, to 5-HTP. These people should not take 5-HTP without
consulting a knowledgeable healthcare professional. The safety of taking 5-HTP during
pregnancy and breast-feeding is not known at this time.
Avoid prolonged exposure to sunlight. 5-hydroxytryptophan may increase the sensitivity of
your skin to the sun. Use a sunscreen and wear protective clothing when exposure to the
sun is unavoidable.
|
|
|
Dosing
In a controlled trial, 5-HTP (300 mg per day) was shown to be effective in reducing many
symptoms of fibromyalgia, including pain, morning stiffness, sleep disturbances, and
anxiety.
For depression, 300 mg per day is often effective, though much of the research used 5-HTP
in combination with drugs or was uncontrolled.
For insomnia, a single 100-mg nighttime
dose of 5-HTP was sufficient to improve the duration and depth of sleep in one
placebo-controlled trial.
For migraine headaches, amounts ranging from 400–600 mg per day
have been shown to be effective at reducing the frequency and severity of attacks in most
clinical trials.
For tension headaches, 100 mg of 5-HTP taken three times per day led to
a significant decrease in consumption of pain-relievers, but no significant change in
headache duration or intensity.
Appetite reduction and weight loss (averaging 11 pounds in 12 weeks) has occurred with
amounts of 600–900 mg daily. In another clinical trial, 750 mg per day has been shown to
be effective at decreasing carbohydrate and fat intake, and promoting weight loss.
|
|
|
Drug Interactions
Certain medicines interact with 5-hydroxytryptophan: Some interactions may increase the
need for 5-hydroxytryptophan (Beneficial), other interactions may be negative (Avoid) and
indicate 5-hydroxytryptophan should not be taken without first speaking with your
physician or pharmacist, others may require further explanation (Check).
- Carbidopa - Check
- Carbidopa/Levodopa - Check
- Fluoxetine - Avoid
- Fluvoxamine - Avoid
- Paroxetine - Avoid
- Sertraline - Avoid
- Sibutramine - Avoid
- Sumatriptan - Avoid
- Tramadol - Avoid
- Venlafaxine - Avoid
- Zolmitriptan - Avoid
- Zolpidem - Avoid
|
|
|
|
Sources:
- Belongia EA, Hedberg CW, Gleich GJ, et al. An investigation of the cause of the
eosinophilia-myalgia syndrome associated with tryptophan use. N Engl J Med 1990;323:357–65.
- Martin RW, Duffy J, Engel AG, et al. The clinical spectrum of the eosinophilia-myalgia
syndrome associated with L-tryptophan ingestion. Clinical features in 20 patients and
aspects of pathophysiology. Ann Intern Med 1990;113:124–34.
- Mayeno AN, Lin F, Foote CS, et al. Characterization of "peak E," a novel amino acid
associated with eosinophilia-myalgia syndrome. Science 1990;250:1707–8.
- Belongia EA, Hedberg CW, Gleich GJ, et al. An investigation of the cause of the
eosinophilia-myalgia syndrome associated with tryptophan use. N Engl J Med 1990;323:357–65.
- Reinauer S, Plewig G. [Eosinophilia-myalgia syndrome]. Hautarzt 1991;42(3):137–9 [in
German].
- Toyo'oka T, Yamazaki T, Tanimoto T, et al. Characterization of contaminants in
EMS-associated L-tryptophan samples by high-performance liquid chromatography. Chem Pharm
Bull (Tokyo) 1991;39(3):820–2.
- Trucksess MW, Thomas FS, Page SW. High-performance liquid chromatographic determination
of 1,1'-ethylidenebis(L-tryptophan) in L-tryptophan preparations. J Pharm Sci
1994;83(5):720–2.
- Trucksess MW. Separation and isolation of trace impurities in L-tryptophan by
high-performance liquid chromatography. J Chromatogr 1993;630(1–2):147–50.
- Ito J, Hosaki Y, Torigoe Y, Sakimoto K. Identification of substances formed by
decomposition of peak E substance in tryptophan. Food Chem Toxicol 1992;30(1):71–81.
- Castot A, Bidault I, Bournerias I, et al. ["Eosinophilia-myalgia" syndrome due to
L-tryptophan containing products. Cooperative evaluation of French Regional Centers of
Pharmacovigilance. Analysis of 24 cases]. Therapie 1991;46(5):355–65.
- Michelson D, Page SW, Casey R, et al. An eosinophilia-myalgia syndrome related disorder
associated with exposure to L-5-hydroxytryptophan. J Rheumatol 1994;21:2261–5.
- Sternberg EM, Van Woert MH, Young SN, et al. Development of a scleroderma-like illness
during therapy with L-5-hydroxytryptophan and carbidopa. N Engl J Med 1980;303(14):782–7.
- Johnson KL, Klarskov K, Benson LM, et al. Presence of peak X and related compounds:
the reported contaminant in case related 5-Hydroxy-L-tryptophan associated with
eosinophilia-myalgia syndrome. J Rheumatol 1999;26(12):2714–7.
- Hagan JJ, Hatcher JP, Slade PD. The role of 5-HT1D and 5-HT1A receptors in mediating
5-hydroxytryptophan induced myoclonic jerks in guinea pigs. Eur J Pharmacol
1995;294:743–51.
- Green AR, Johnson P, Mountford JA, Nimgaonkar VL. Some anticonvulsant drugs alter
monoamine mediated behaviour in mice in ways similar to electroconvulsive shock;
implications for antidepressant therapy. Br J Pharmacol 1985;84:337–46.
- Bourin M, Hascoet M, Deguiral P. 5-HTP induced diarrhea as a carcinoid syndrome model
in mice? Fundam Clin Pharmacol 1996;10:450–7.
- Hirai M, Nakajima T. Biochemical studies on the mechanism of difference in the renal
toxicity of 5-hydroxy-L-tryptophan between Sprague Dawley and Wistar rats. J Biochem
(Tokyo) 1979;86:907–13.
- Martin TG. Serotonin syndrome. Ann Emerg Med 1996;28:520–6.
- Sternberg EM, Van Woert MH, Young SN, et al. Development of a scleroderma-like illness
during therapy with L-5-hydroxytryptophan and carbidopa. N Engl J Med 1980;303:782–7.
|
|
|